[1] |
International Agency for Research on Cancer. Global cancer observatory[EB/OL]. (2020-7-15).
URL
|
[2] |
方友强, 周祥福. 2020版美国国立综合癌症网络前列腺癌临床实践指南要点解读 [J/CD]. 中华腔镜泌尿外科杂志(电子版), 2020, 14(6): 405-8.
|
[3] |
黄健, 王建业, 孔垂泽,等. 中国泌尿外科和男科疾病诊断治疗指南 [M]. 第一版,北京: 科学出版社, 2020.
|
[4] |
Ahmed HU, EL-shater bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study[J]. Lancet (London, England), 2017, 389(10071): 815-822.
|
[5] |
Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy [J]. Eur Urol, 2013, 64(6): 876-892.
|
[6] |
Drost FH, Osses DF, Nieboer D, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer[J]. Cochrane Database Syst Rev, 2019, 4(4): Cd012663.
|
[7] |
Scheltema MJ, Chang JI, Stricker PD, et al. Diagnostic accuracy of (68) Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of (68) Ga-PSMA PET to mpMRI[J]. BJU Int, 2019, 124 Suppl 1: 42-49.
|
[8] |
Donato P, Roberts MJ, Morton A, et al. Improved specificity with (68)Ga PSMA PET/CT to detect clinically significant lesions "invisible" on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology [J]. Eur J Nucl Med Mol Imaging, 2019, 46(1): 20-30.
|
[9] |
Berger I, Annabattula C, Lewis J, et al. (68)Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology[J]. Prostate Cancer Prostatic Dis, 2018, 21(2): 204-211.
|
[10] |
Alberts AR, Roobol MJ, Verbeek JFM, et al. Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging: improving the rotterdam european randomized study of screening for prostate cancer risk calculators[J]. Eur Urol, 2019, 75(2): 310-318.
|
[11] |
Yu S, Hong G, Tao J, et al. Multivariable models incorporating multiparametric magnetic resonance imaging efficiently predict results of prostate biopsy and reduce unnecessary biopsy[J]. Front In col, 2020, 10(2442).
|
[12] |
Hu X, Cammann H, Meyer h- A, et al. Artificial neural networks and prostate cancer-tools for diagnosis and management [J]. Nat Rev Urol, 2013, 10(3): 174-182.
|
[13] |
Delong e R, Delong DM, Clarke-pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach [J]. Biometrics, 1988, 44(3): 837-845.
|
[14] |
Xing NZ, Wang MS, Fu Q, et al. Feasibility of prostatectomy without prostate biopsy in the era of new imaging technology and minimally invasive techniques [J]. World J Clin Cases, 2019, 7(12): 1403-1409.
|
[15] |
European Association of Urology. EAU guidelines on prostate cancer [EB/OL]. (2020-5-8).
URL
|
[16] |
陈东, 李志勇, 李永红, 等. 机器人辅助前列腺癌根治术对比开放前列腺癌根治术:孰优孰劣? [J/CD]. 中华腔镜泌尿外科杂志(电子版), 2019, 13(4): 217-220.
|
[17] |
Hung AJ, Chen J, Che Z, et al. Utilizing machine learning and automated performance metrics to evaluate robot-assisted radical prostatectomy performance and predict outcomes[J]. J Endourol, 2018, 32(5): 438-444.
|
[18] |
罗进阳, 郑嘉欣, 蔡宗龙, 等. 基于第二版PI-RADS建立的预测模型对前列腺穿刺活检结果的预测价值 [J]. 中华泌尿外科杂志, 2019, 40(9): 673-679.
|
[19] |
Wu YS, Zhang N, Liu SH, et al. The Huashan risk calculators performed better in prediction of prostate cancer in Chinese population: a training study followed by a validation study[J]. Asian J Androl, 2016, 18(6): 925-929.
|
[20] |
Chen R, Xie L, Xue W, et al. Development and external multicenter validation of chinese prostate cancer consortium prostate cancer risk calculator for initial prostate biopsy[J]. Urol Oncol, 2016, 34(9): 416.e1-7.
|
[21] |
Verbeek JFM, Bangma CH, Kweldam CF, et al. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore [J]. Urol Oncol, 2019, 37(2): 138-144.
|
[22] |
Tomlins SA, Day JR, Lonigro RJ, et al. Urine TMPRSS2:ERG Plus PCA3 for individualized prostate cancer risk assessment[J]. European urology, 2016, 70(1): 45-53.
|
[23] |
Hansen J, Auprich M, Ahyai SA, et al. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay[J]. European urology, 2013, 63(2): 201-209.
|